Skip to search formSkip to main contentSkip to account menu

ibritumomab tiuxetan

Known as: ibritumomab tiuxetan [Chemical/Ingredient] 
A monoclonal antibody that is used to treat certain types of B-cell non-Hodgkin lymphoma and is being studied in the treatment and detection of other… 
National Institutes of Health

Related topics

Related topics

14 relations
B-Cell LymphomasDrug AllergyHuman B-Lymphocyte Antigen CD20, humanLactation

Narrower (4)

IDEC-Y2B8Murine Monoclonal Antibody 2B8Zevalinyttrium-90-ibritumomab tiuxetan

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2006
Review
2006
Ibritumomab tiuxetan for non-Hodgkin’s lymphoma
Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B… 
Review
2005
Review
2005
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
AIM Yttrium-90 ((90)Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy is an effective treatment for relapsed or refractory B… 
2005
2005
Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy.
2004
2004
Yttrium‐90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome
90Y ibritumomab tiuxetan is a radioimmunotherapeutic construct that is reported to be an effective treatment for patients with… 
Review
2004
Review
2004
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation… 
2004
2004
Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan.
UNLABELLED This investigation examined the accuracy of dose calibrator activity measurement of the beta-emitting… 
Review
2004
Review
2004
Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
Targeted radioimmunotherapy, including yttrium 90-labeled ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar… 
Review
2003
Review
2003
Radioimmunotherapy for NHL: Experience of 90Y-Ibritumomab Tiuxetan in Clinical Practice
Radioimmunotherapy (RIT) is a novel treatment modality that combines the benefits of radiotherapy and immunotherapy, enabling… 
Review
2002
Review
2002
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New… 
Review
2002
Review
2002
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
Radioimmunotherapy (RIT) is a new treatment modality for B-cell non-Hodgkin's lymphoma (NHL). Recent clinical trials have clearly… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)